Company intelligence / Profile preview

Klinea

Ownership: Private
Development stage: Other

Overview

Klinea is an active European engineering and consultancy firm specializing in the design, optimization, and validation of biopharmaceutical facilities. The company supports clients across advanced therapies (gene/cell/tissue), vaccines, recombinant proteins/biomolecules, animal health products, and general drugs. With over 20 years of experience and more than 180 projects delivered globally, it acts as a strategic partner for laboratories seeking to meet cGMP requirements from R&D through commercial production.

Modalities: Recombinant proteinMonoclonal antibodyAdvanced therapy (cell therapy, gene therapy)Vaccine
Industry: Consulting

Partnerships

Not specifically listed in public sources. The company works with various biopharma clients on facility projects but no major pharma partnerships are named in available data.

Beyond the preview

Go deeper on Klinea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Klinea.

Explore the full profile